U.S. Markets closed

Amgen’s Nephrology Drugs: Aranesp, Epogen, Sensipar in 4Q17

Daniel Collins
Amgen’s Nephrology Drugs: Aranesp, Epogen, Sensipar in 4Q17

In 4Q17, Amgen’s (AMGN) Aranesp generated revenues of $491 million, which reflected a 7% decline on a YoY (year-over-year) basis and a 5% decline quarter-over-quarter. In 4Q17 in the US and international markets, Aranesp generated revenues of $263 million and $228 million, respectively. Lower unit demand and unfavorable changes in foreign exchange rates primarily led to the decline in revenues in 4Q17.